Balyasny Asset Management LLC Axsome Therapeutics, Inc. Call Options Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2025 Nov 14, 2025	BUY	$100.39 - $129.29 $140,546 - $181,006	1,400 Added 27.45%	6,500 $789,000
Q2 2025 Aug 14, 2025	SELL	$95.65 - $116.49 $172,170 - $209,682	-1,800 Reduced 26.09%	5,100 $532,000
Q1 2025 May 15, 2025	BUY	$80.05 - $137.75 $552,345 - $950,475	6,900 New	6,900 $804,000
Q3 2024 Nov 14, 2024	BUY	$78.93 - $95.84 $370,971 - $450,448	4,700 New	4,700 $422,000
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $2.28 Million - $3.52 Million	39,000 New	39,000 $2.8 Million
Q4 2020 Feb 16, 2021	SELL	$66.31 - $86.52 $2.65 Million - $3.46 Million	-40,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$68.34 - $85.84 $2.73 Million - $3.43 Million	40,000 New	40,000 $2.85 Million

414

36.8M

752K

567K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $5.99B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.